Samsung takes on clinical manufacturing of Ichnos’ mAb candidate

By Vassia Barba

- Last updated on GMT

(Image: Getty/Robert Daly)
(Image: Getty/Robert Daly)

Related tags Ichnos Sciences Samsung biologics Monoclonal antibody Monoclonal antibodies

Samsung continues an agreement formerly signed with Glenmark to manufacture Ichnos’ mAb treatment candidate for atopic dermatitis, as the product enters Phase III clinical trials.

Samsung Biologics announced the signing of an agreement with Ichnos to manufacture the drug substance for ISB 830, a monoclonal antibody (mAb) against receptor OX40, which is currently in development as a potential treatment for moderate-to-severe atopic dermatitis.

Additionally, the product has a mechanism of action that enables the treatment of ‘a range of autoimmune diseases’, including atopic dermatitis, the companies stated.

The agreement comes as Ichnos has completed enrollment in a Phase IIb clinical study for ISB 830, with results expected during the first half of 2020, and prepares to advance the candidate into Phase III clinical trials.

A spin-out company of Glenmark, Ichnos was launched earlier this month​ with a portfolio of five clinical stage assets across the oncology, autoimmune disease, and pain therapeutics areas. 

Samsung had signed an agreement to provide process development and manufacturing services for ISB 830 with Glenmark in 2017. 

According to the companies, the prevalence of atopic dermatitis in seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients, with the market expected to grow to $18.3bn (€16.53bn) by 2027.

Related topics Bio Developments Bio-Outsourcing

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars